Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05475925 · ClinicalTrials.gov registry record · Phase 1
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
A Phase 1 study of Hepatosplenic T-cell Lymphoma and Enteropathy-Associated T-Cell Lymphoma, sponsored by Dren Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT05475925: Recruiting Phase 1 study of Hepatosplenic T-cell Lymphoma and Enteropathy-Associated T-Cell Lymphoma, sponsored by Dren Bio.
NCT05475925 is a Phase 1 study of Hepatosplenic T-cell Lymphoma and Enteropathy-Associated T-Cell Lymphoma that is actively recruiting participants, run by Dren Bio. The registered enrollment target is 69 participants, below the 89-participant average among 12 other Hepatosplenic T-cell Lymphoma trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05475925, a Phase 1 study of Hepatosplenic T-cell Lymphoma and Enteropathy-Associated T-Cell Lymphoma, is actively recruiting participants, sponsored by Dren Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Conditions Studied
Interventions
- DRUG DR-01
Study Locations (20)
California
- Dren Investigational Site - Duarte
- Dren Investigational Site - Irvine
- Dren Investigational Site - Redwood City
New York
- Dren Investigational Site 1 - New York
- Dren Investigational Site 2 - New York
Virginia
- Dren Investigational Site - Charlottesville
- Dren Investigational Site - Fairfax
Victoria
- Dren Investigational Site - Clayton
- Dren Investigational Site - Richmond
Other
- Dren Investigational Site - Pierre-Bénite
- Dren Investigational Site - Rennes
Alabama
- Dren Investigational Site - Birmingham
Connecticut
- Dren Investigational Site - New Haven
Florida
- Dren Investigational Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05475925 shows while recruiting
NCT05475925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 89-participant average among 12 other Hepatosplenic T-cell Lymphoma trials with a reported enrollment target (22% lower).
The record links to 10 conditions, with Hepatosplenic T-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which DR-01 is the first listed.
NCT05475925 names 20 study sites across 14 states, led by California, New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT05475925 about?
NCT05475925 is a clinical study titled "A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas". This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
What is the current status of trial NCT05475925?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2022-07-13. Estimated completion is 2026-12.
What conditions does trial NCT05475925 study?
This clinical trial studies the following conditions: Hepatosplenic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Aggressive NK-cell Leukemia, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, LGLL - Large Granular Lymphocytic Leukemia.
What interventions are being tested in trial NCT05475925?
The interventions under investigation include: DR-01 (DRUG).
Who is sponsoring clinical trial NCT05475925?
This trial is sponsored by Dren Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05475925 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatosplenic T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05475925's enrollment target sits among peer trials
69 3rd of 12 higher than 10 of 12 other Hepatosplenic T-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatosplenic T-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
COMPLETED · Phase 1
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
COMPLETED · Phase 1
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
-
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI